Recent News

• 03.26.2026 - IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results
• 03.20.2026 - iMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare Conference
• 03.13.2026 - Second Study Affirms Superiority of iMDx GraftAssure Assay’s Proprietary dd-cfDNA Combination Model Score
• 03.03.2026 - Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission
• 02.11.2026 - iMDx Announces $26.0 Million Registered Direct Offering
• 01.13.2026 - IMDX Supports AST and ASHI STAR Working Group’s Call for Decentralized Transplant Monitoring
• 01.07.2026 - iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation
• 01.06.2026 - iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch
• 01.05.2026 - iMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion

Recent Filings

• 03.26.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.26.2026 - EX-99.1 EX-99.1
• 03.26.2026 - 8-K Current report
• 02.26.2026 - 8-K Current report
• 02.12.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.12.2026 - 8-K Current report
• 02.12.2026 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 02.12.2026 - EX-99.1 EX-99.1
• 02.11.2026 - EX-99.1 EX-99.1
• 02.11.2026 - 424B5 Prospectus [Rule 424(b)(5)]